An Incredible Year at ATCC

It's incredible to reflect on how ATCC has supported the global scientific community for the past 99 years. From providing the strain that helped develop Polymerase Chain Reaction (PCR), a method for detecting tiny quantities of genetic material, in the mid-1980s to now providing advanced biological models to speed the discovery and development of therapeutics, ATCC has long served as a springboard for numerous scientific breakthroughs. 

As we’ve done for the last 99 years, in 2024 ATCC worked to advance important scientific research and the mission of government health agencies. We provided innovative products and services to advance drug discovery and development. We partnered with the federal government to support global health initiatives and the safety and security of the American public. We expanded our global reach and continue to reward and recognize our team members who make this important work possible. We are proud to share a few of our accomplishments from this year:

Advancing Scientific Research

ATCC prides itself on our unwavering commitment to upholding the integrity and veracity of sound science. We honor this commitment by providing innovative products and services, sharing our research through scientific papers, posters, webinars, blog posts, and podcasts, and serving as subject matter experts on scientific topics in the media. In 2024, ATCC contributed to advancing scientific research by:

• Offering a new product line of precisely quantitated microbial reference materials, MicroQuant™, used to streamline microbial quality control testing in pharmaceutical manufacturing.
• Enabling researchers to get faster results from critical assays with ThawReady™ cells.
• Ensuring the highest quality and performance for drug development needs with our HepatoXcell™ Primary Human Hepatocytes.
• Helping food manufacturers and stakeholders address challenges, meet industry standards, and advance scientific knowledge in the field of food production and biotechnology.
• Growing our collection by adding 217 accessions, including contemporary influenza strains and highly characterized antibiotic-resistant strains.
• Launching several new in vitro models including 5 immuno-oncology reporter cell lines, 7 HCMI organoid models, and 42 molecular standards, including a synthetic Avian Influenza standard. We also rebuilt NIH/3T3, which was a top selling cell line that had lost one of its key properties.
• Continuing to provide researchers with high-quality, annotated data to perform bioinformatics analyses and make insightful correlations by offering 5,084 microbial genomes through our ATCC Genome Portal.
• Hosting 16 webinars highlighting innovative research and development being performed by thought leaders in science for more than 3,000 registrants.
• Publishing 26 posts on our blog, Credible Conversations, highlighting the impactful and innovative work being done at ATCC.
• Sharing 15 Behind the Biology podcast episodes featuring discussions between ATCC experts, collaboration partners, and industry leaders.
• Presenting 38 scientific posters at conferences, meetings, and tradeshows to showcase research findings to the scientific community, initiate important conversations, and promote future collaborations.
• Publishing 11 peer-reviewed publications highlighting our scientific presence in immuno-oncology, extracellular vesicles, infectious disease, microphysiological systems, cellular pathology, genomics, and more.
• Contributing to 10 industry articles in Biocompare, BioPharm International, Chemical & Engineering News, Technology Networks, and more, showcasing ATCC’s expertise in various scientific fields.

Supporting the Federal Government’s Global Health Initiatives

ATCC’s Federal Solutions Team continues to accomplish incredible work in supporting public health initiatives for the US government. Year to date, ATCC has been awarded 16 new contracts with a total overall value of $171 million, including a grant from NIH to build a new Biomanufacturing Suite at our Manassas, VA, Headquarters.

Learn more about a few of these awards and projects:

• ATCC Announces New Award from BARDA to Provide Centralized Storage and Bioprocessing Services for Project NextGen
• ATCC Announces Award from the National Cancer Institute to Provide Biospecimen Processing Services and Assays for Cancer Research
• ATCC Announces Award from NIAID to Provide Antiviral Screening Assays Relevant to Human Diseases
• ATCC Receives Grant from Commonwealth’s Development Opportunity Fund to Apply Toward Its New Biomanufacturing Suite in Virginia
• ATCC Announces Award from NIAID to Support Preclinical Models of Infectious Diseases
• ATCC Announces Subaward to Advance Research for Tickborne Diseases and Vaccine Development

Expanding Our Global Reach

ATCC has consistently demonstrated its commitment to advancing science and supporting researchers worldwide. In 2024, this commitment took on a new dimension as we expanded our presence in international markets, celebrated key milestones, and deepened partnerships that enable us to better serve our global customer base.

Since the post-COVID period, ATCC has actively expanded its distribution network in emerging markets including the Philippines, Vietnam, and Indonesia. To emphasize our commitment to international growth in 2024, our International Sales Team and Product Managers attended International Conferences, conducted Industry seminars, and visited international key opinion leaders supporting our distributors in the UK, China, India, Korea, Singapore, and Japan. 

ATCC also remained focused on making our products available in the Asia-Pacific region. We added a second distributor in Hong Kong, Genetimes ExCell International Holdings Limited, and commemorated the 20^th anniversary of Beijing Zhong Yuan as ATCC's trusted distributor in the region.

Recognizing & Celebrating Our Employees

Our employees are scientists and professionals in various fields driven by our common goal of advancing and applying scientific discovery. We proudly reward our employees through our internal recognition program and career development, and provide engaging experiences for employees to connect, learn, and have meaningful participation in companywide events.

We are proud to have also received Great Place to Work™ Certification for the second year in a row. This year, 100+ employees received promotions and 100 people joined the ATCC Team!

For nearly 100 years, ATCC has served its mission to support the advancement and application of scientific knowledge. We are focused on transforming global health through science, now and in the future. We look forward to celebrating our Centennial Anniversary with you in 2025!

Did you know?

ATCC is transforming drug development and our understanding of human diseases through its Microphysiological Systems (MPS) program.